Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study
Authors' conclusion
In adults with basal insulin-treated T2D, use of CGM compared with BGM resulted in rapidly improved glycemic management, with a substantial reduction in HbA1c over 3 months.
Study context
- Population
- Adults with T2D treated with basal insulin without prandial insulin
- Participants
- 175 adults
- Comparison
- Real-time continuous glucose monitoring (CGM) vs blood glucose monitoring (BGM)
- CGMn = 116
- BGMn = 59reference
- Primary endpoint
- Between-group difference in hemoglobin A1c (HbA1c) adjusted for baseline value
- Follow-up
- 3 months
Methodological detailsrandomized 2:1, 3-month analysis
- Randomized 2:1
- 3-month analysis
Primary result
As reported in the abstract
HbA1c
Each group vs BGMAdjusted difference, % (95% CI)P value
CGM
−0.6(−0.9% to −0.3%)
P < 0.001Each group vs BGMAdjusted difference, mmol/mol (95% CI)P value
CGM
−6.6(−10.2 to −2.9)
P < 0.001Further findings
| Outcome | Adjusted difference (%) (95% CI) | P value | |
|---|---|---|---|
| Time >250 mg/dL · 3 months | −5.8 (−10.4% to −1.2%) | P < 0.001 | |
| −15−10−505Difference, % (linear scale) |
| Outcome | Adjusted difference (%) (95% CI) | P value |
|---|---|---|
| TIR 70-180 mg/dL · 3 months | +9.3 (2.1%–16.4%) | P < 0.001 |
CGM metrics in first 7 days (CGM group)
- Significant improvements in CGM metrics during the first 7 days of CGM use
Safety
| Outcome | Adjusted difference (events per week) (95% CI) | P value | |
|---|---|---|---|
| Hypoglycaemia · 3 monthsMean weekly hypoglycemic event rate | −0.2 (−0.4 to −0.1) | P < 0.001 | |
| −0.6−0.4−0.200.2Difference, events per week (linear scale) |
Hypoglycaemia · 3 months
- No increase in time <70 mg/dL with CGM
Original publication
Rapid improvements in glycemic management with use of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin: 3-month analysis of the MOBILE study. BMJ Open Diabetes Res Care. Published 4 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →